Reg CF · Series Seed-2 Preferred Stock · Dec 2024
ClosedReached targetReg CFPreferred EquityFinancials disclosed in this offering
FY2022–FY2023 · hover for sourceThe fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.
Amendments to this offering
1 amendment- Mar 12, 2025
- Deadline Mar 12, 2025 → Apr 30, 2025
- Target $124K → $20K
“Updated capital resources, and D&O to add COO, removed CTO. Revised FDA product use on campaign page. Increased authorized shares. Lowered minimum to $20K and updated use of proceeds.”
Form C/A on EDGAR ↗
Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.
Deal terms
Perks
Offering details
Links & provenance
0001665160-24-001794
Last synced Aug 18, 2026
About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.